Who
Lee Scott Golden
Director
Company insider
Files Form 4 as: Director, Cadrenal Therapeutics; EVP & Chief Medical Officer, PTC Therapeutics; Chief Medical Officer, MetaVia.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $2.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 5 Oct 2016
- Last trade
- 9 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Oct 2026filed 13 Oct 2026 | CVKD Cadrenal Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $56K829 at $67.99 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $56K829 at $67.99 | filing |
| 5 Mar 2026filed 9 Mar 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $634K10,000 at $63.38 | filing |
| 5 Mar 2026filed 9 Mar 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $634K10,000 at $63.38 | filing |
| 18 Feb 2026filed 20 Feb 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $172K2,484 at $69.36 | filing |
| 18 Feb 2026filed 20 Feb 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $172K2,484 at $69.36 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K866 at $76.45 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K866 at $76.45 | filing |
| 7 Jan 2026filed 8 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K642 at $77.48 | filing |
| 7 Jan 2026filed 8 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K642 at $77.48 | filing |
| 6 Jan 2026filed 8 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K1,340 at $76.95 | filing |
| 6 Jan 2026filed 8 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K1,340 at $76.95 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,875 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,875 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
| 2 Dec 2025filed 3 Dec 2025 | CVKD Cadrenal Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 2 Apr 2025filed 4 Apr 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $42K897 at $46.95 | filing |
| 20 Feb 2025filed 21 Feb 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K962 at $50.12 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in StockPTCT · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Lee Scott Golden; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.